Cadrenal Therapeutics, Inc.
CVKD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001937993
No open-market purchases or sales by Cadrenal Therapeutics, Inc. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $379.6K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Cadrenal Therapeutics, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 20 | 19 | −1 |
| Shares | 91.1K | 113.7K | +22.6K (+24.8%) |
| Value | $460.1K | $379.6K | −$80.5K (−17.5%) |
New holders (6)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 29,055 | $97.0K | 0.00% |
| CoreCap Advisors, LLC | 1,285 | $4.29K | 0.00% |
| Grove Bank & Trust | 1,000 | $3.34K | 0.00% |
| Clearstead Advisors, LLC | 650 | $2.17K | 0.00% |
| Quest 10 Wealth Builders, Inc. | 380 | $1.27K | 0.00% |
| Barclays PLC | 93 | $311 | 0.00% |
Sold out (7)
Institutions that held Cadrenal Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| JPMorgan Chase & Co | 7,500 | $31.9K |
| BlackRock, Inc. | 5,496 | $28.1K |
| Cygnus Capital Advisors, LLC | 1,492 | $8.00K |
| RWM Asset Management, LLC | 200 | $1.02K |
| Harbour Investments, Inc. | 100 | $512 |
| Citigroup Inc | 1 | $5 |
| Curio Wealth, LLC | 1 | $5 |